The use of different doses of metamizol for post-operative analgesia in dogs

Imagawa, Vivianne Higuchi; Fantoni, Denise Tabacchi; Tatarunas, Angélica Cecília; Mastrocinque, Sandra; Almeida, Tatiana Ferrante de; Ferreira, Fernando; Posso, Irimar de Paula

doi:10.1111/j.1467-2995.2011.00617.x

Cited by 52 publications

(62 citation statements)

References 44 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Very good effects have been attained in treatment of acute pain using metamizole in combination with NSAIDs, including ketoprofen (Oberhofer et al 2005) or with opioid analgesics (López-Muñ oz et al 2008, Baumgartner et al 2009). The efficacy of metamizole in post-operative pain therapy has been confirmed in studies conducted on humans (Edwards et al 2001, Chaparro et al 2012) and on animals (Imagawa et al 2011). Bigal et al (2002 determined that metamizole administered intravenously was effective for the acute treatment of episodic tension-type headache.…”

Section: Clinical Applications In Peoplementioning

confidence: 74%

“…The situation is different in the case of animals because the producer of the metamizole sodium preparation (Biovetalgin) registered for use on many animal species allows its administration to pregnant and lactating animals. It is thought that metamizole does not demonstrate the contraindications or limitations usually observed with NSAIDs (Edwards et al 2001, Baumgartner et al 2009, Imagawa et al 2011, which is most probably associated with the fact that -unlike most NSAIDs -the drug is a very weak inhibitor of COX-1. For instance, it is acceptable to administer metamizole to patients with gastric ulcerations, which are a contraindication to the use of NSAIDs (Pyralgin, summary of product characteristic, Sánchez et al 2002, Imagawa et al 2011.…”

Section: Contraindicationsmentioning

confidence: 99%

“…Compared to opoid analgesics or NSAIDs, there are few contraindications for use of metamizole in humans and animals (Baumgartner et al 2009, Imagawa et al 2011. Due to a possible haematotoxic effect, the drug is contraindicated in patients with a history or presence of blood dyscrasia.…”

Section: Contraindicationsmentioning

confidence: 99%

“…Compared to other non-opioid analgesics, metamizole seems to be a relatively safe drug (Bigal et al 2002, Imagawa et al 2011. The most common adverse effects are: gastrointestinal disorders, such as nausea, vomiting, abdominal pain and diarrhea (Edwards et al 2001).…”

Section: Side Effectsmentioning

confidence: 99%

“…Sweden, the USA, Japan, the UK, Australia and Iran), but in many more countries (some European states, Asia, South America) it is still broadly used, both in human medicine (as an OTC drug) and in veterinary practice (Edwards et al 2001, Wessel et al 2006, Baumgartner et al 2009, Imagawa et al 2011. In Canada, metamizole is registered for use only on small animals and horses, whereas in the USA it has been prohibited from use on food producing animals (Fajt 2001, Smith et al 2008).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Pharmacological characteristics of metamizole

Jasiecka¹,

Maślanka²,

Jaroszewski³

2014

Polish Journal of Veterinary Sciences

126

View full text Add to dashboard Cite

Metamizole (dipyrone) is a popular analgetic, non-opioid drug, commonly used in human and veterinary medicine. In some cases, this agent is still incorrectly classified as a non-steroidal anti-inflammatory drug (NSAID). Metamizole is a pro-drug, which spontaneously breaks down after oral administration to structurally related pyrazolone compounds. Apart from its analgesic effect, the medication is an antipyretic and spasmolytic agent. The mechanism responsible for the analgesic effect is a complex one, and most probably rests on the inhibition of a central cyclooxygenase-3 and activation of the opioidergic system and cannabinoid system. Metamizole can block both PG-dependent and PG-independent pathways of fever induced by LPS, which suggests that this drug has a profile of antipyretic action distinctly different from that of NSAIDs. The mechanism responsible for the spasmolytic effect of metamizole is associated with the inhibited release of intracellular Ca 2+ as a result of the reduced synthesis of inositol phosphate. Metamizole is predominantly applied in the therapy of pain of different etiology, of spastic conditions, especially affecting the digestive tract, and of fever refractory to other treatments. Co-administration of morphine and metamizole produces superadditive, antinociceptive effects. Metamizole is a relatively safe pharmaceutical preparation although it is not completely free from undesirable effects. Among these side-effects, the most serious one that raises most controversy is the myelotoxic effect. It seems that in the past the risk of metamizole-induced agranulocytosis was exaggerated. Despite the evidence showing no risk of teratogenic and embryotoxic effects, the drug must not be administered to pregnant women, although it is allowed to be given to pregnant and lactating animals. This paper seeks to describe the characteristics of metamizole in the light of current knowledge.

show abstract